TRPV4-KCa2.3 Coupling Compound for Targeted Hypertension Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antihypertensive drugs have non-specific targets and numerous side effects, necessitating the development of a small molecule that can specifically enhance the coupling of TRPV4 and KCa2.3 channels to treat hypertension with fewer side effects.
Innovation Solution
A compound with a specific structure is designed to enhance the spatial coupling of the TRPV4-KCa2.3 complex, which is formulated into various pharmaceutical preparations for oral, parenteral, and topical administration, including combinations with other antihypertensive drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antihypertensive drugs are used, then hypertension can be treated, but the drugs have non-specific targets and numerous side effects
Solution Approach 1:
The patent applies local quality by designing a compound that specifically targets the TRPV4-KCa2.3 channel complex interface rather than acting on multiple non-specific targets. The compound's molecular structure is optimized to interact locally at the specific binding interface between TRPV4 and KCa2.3 channels, providing selective action on the intended target while avoiding off-target effects that cause side effects in conventional antihypertensive drugs
Solution Approach 2:
The compound acts as an intermediary molecule that enhances the coupling between TRPV4 and KCa2.3 channels. Rather than directly opening channels or blocking receptors, it mediates the interaction between these two channels, facilitating their functional coupling and thereby producing the desired physiological effect through a specific molecular mechanism that reduces non-specific interactions
2Object-generated harmful factors
If a small molecule is designed to specifically enhance TRPV4-KCa2.3 coupling, then side effects are reduced, but metabolic stability and bioavailability need improvement
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the compound's molecular parameters including hydrophobicity, molecular weight, and structural rigidity. These parameter adjustments are made to achieve the right balance between metabolic stability (resistance to degradation) and bioavailability (ability to reach the target), while maintaining the compound's specific action on the TRPV4-KCa2.3 complex to minimize side effects
Data Source
AI summary
The present disclosure provides a compound for specifically enhancing the spatial coupling degree of a TRPV4-KCa2.3 complex and use thereof, and belongs to the field of chemical medicine. The compound with a structure shown in a general formula (I) in the present disclosure is mainly used for re-coupling two uncoupled proteins and restoring the proteins to a normal state under uncoupling of TRPV4 and KCa2.3 in hypertensive patients. Under normal conditions of the TRPV4 and the KCa2.3, a signal of calcium ions is received by the TRPV4. As the calcium ions flow in, potassium ions in a KCa2.3 channel in the downstream are stimulated to flow out. Due to depolarization, vasodilation is caused, and therefore, the blood pressure of the hypertensive patients is returned to a normal level.